Polyphenolic grape stalk and coffee extracts attenuate spinal cord injury-induced neuropathic pain development in ICR-CD1 female mice.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 Sep 2022
02 Sep 2022
Historique:
received:
29
03
2022
accepted:
24
08
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
More than half of spinal cord injury (SCI) patients develop central neuropathic pain (CNP), which is largely refractory to current treatments. Considering the preclinical evidence showing that polyphenolic compounds may exert antinociceptive effects, the present work aimed to study preventive effects on SCI-induced CNP development by repeated administration of two vegetal polyphenolic extracts: grape stalk extract (GSE) and coffee extract (CE). Thermal hyperalgesia and mechanical allodynia were evaluated at 7, 14 and 21 days postinjury. Then, gliosis, ERK phosphorylation and the expression of CCL2 and CX3CL1 chemokines and their receptors, CCR2 and CX3CR1, were analyzed in the spinal cord. Gliosis and CX3CL1/CX3CR1 expression were also analyzed in the anterior cingulate cortex (ACC) and periaqueductal gray matter (PAG) since they are supraspinal structures involved in pain perception and modulation. GSE and CE treatments modulated pain behaviors accompanied by reduced gliosis in the spinal cord and both treatments modulated neuron-glia crosstalk-related biomolecules expression. Moreover, both extracts attenuated astrogliosis in the ACC and PAG as well as microgliosis in the ACC with an increased M2 subpopulation of microglial cells in the PAG. Finally, GSE and CE prevented CX3CL1/CX3CR1 upregulation in the PAG, and modulated their expression in ACC. These findings suggest that repeated administrations of either GSE or CE after SCI may be suitable pharmacologic strategies to attenuate SCI-induced CNP development by means of spinal and supraspinal neuroinflammation modulation.
Identifiants
pubmed: 36056079
doi: 10.1038/s41598-022-19109-4
pii: 10.1038/s41598-022-19109-4
pmc: PMC9440260
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14980Informations de copyright
© 2022. The Author(s).
Références
Neurochem Res. 2015 Sep;40(9):1792-8
pubmed: 26152332
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10655-60
pubmed: 17551020
J Nat Med. 2013 Oct;67(4):698-704
pubmed: 23203628
Food Funct. 2017 Jun 21;8(6):2275-2282
pubmed: 28561817
Neural Plast. 2017;2017:2480689
pubmed: 28951789
Front Cell Neurosci. 2014 May 07;8:121
pubmed: 24847207
J Ultrastruct Res. 1967 Aug;19(3):273-82
pubmed: 4167848
Front Pharmacol. 2019 Mar 22;10:222
pubmed: 30967775
Neurotoxicol Teratol. 2020 Sep - Oct;81:106905
pubmed: 32534151
J Neurosci. 2009 May 27;29(21):6945-54
pubmed: 19474321
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8075-80
pubmed: 10869418
Toxicol Rep. 2019 Jun 07;6:505-513
pubmed: 31211096
J Appl Toxicol. 1990 Aug;10(4):267-74
pubmed: 2202754
J Pain. 2009 Sep;10(9):895-926
pubmed: 19712899
Neurosci Lett. 2013 May 24;543:64-8
pubmed: 23570727
Behav Pharmacol. 2018 Apr;29(2 and 3-Spec Issue):270-279
pubmed: 28590304
J Pain. 2009 Jun;10(6):619-27
pubmed: 19398383
Cell Physiol Biochem. 2016;39(3):1152-64
pubmed: 27576607
Nat Neurosci. 2016 Mar;19(3):504-16
pubmed: 26780511
Chem Biol Interact. 2016 May 25;252:131-40
pubmed: 27087131
Curr Pharm Biotechnol. 2011 Oct;12(10):1707-14
pubmed: 21466443
J Med Food. 2014 Jun;17(6):730-2
pubmed: 24611441
Neurochem Int. 2019 Mar;124:181-192
pubmed: 30664898
Mutat Res. 2005 Nov 11;579(1-2):200-13
pubmed: 16126236
J Pain. 2005 Jul;6(7):434-8
pubmed: 15993821
Neuropharmacology. 2014 Feb;77:100-19
pubmed: 24071567
Toxicol Pathol. 1986;14(1):26-36
pubmed: 3715329
Eur J Pain. 2017 Jan;21(1):29-44
pubmed: 27341614
Eur J Pain. 2009 Mar;13(3):263-72
pubmed: 18554968
J Neuroinflammation. 2021 Sep 12;18(1):196
pubmed: 34511129
Pharmacol Res. 2020 Feb;152:104636
pubmed: 31926275
Eur J Neurosci. 2004 Nov;20(9):2294-302
pubmed: 15525271
Nat Rev Dis Primers. 2017 Apr 27;3:17018
pubmed: 28447605
Neurosci Bull. 2018 Feb;34(1):13-21
pubmed: 28265898
J Neurochem. 2017 May;141(4):486-498
pubmed: 28251660
Mol Neurobiol. 2020 Jan;57(1):96-104
pubmed: 31832973
Curr Psychiatry Rep. 2013 Dec;15(12):421
pubmed: 24214740
Eur J Pain. 2016 Mar;20(3):341-52
pubmed: 25913854
Food Chem Toxicol. 2007 Sep;45(9):1551-7
pubmed: 17658209
Int J Mol Sci. 2018 May 09;19(5):
pubmed: 29747437
Neurobiol Dis. 2020 Nov;145:105077
pubmed: 32898645
J Ethnopharmacol. 2021 Nov 15;280:114455
pubmed: 34320383
Eur J Pharmacol. 2014 Jan 15;723:459-64
pubmed: 24184666
Pain Med. 2009 Oct;10(7):1246-59
pubmed: 19818035
Pain. 1983 Jun;16(2):109-110
pubmed: 6877845
Mol Med Rep. 2018 Jan;17(1):1340-1346
pubmed: 29115619
Cells. 2020 Jul 07;9(7):
pubmed: 32645849
Eur Rev Med Pharmacol Sci. 2018 May;22(9):2876-2887
pubmed: 29771441
J Neuroimmunol. 2020 Apr 15;341:577164
pubmed: 32007785
Eur J Pharmacol. 2021 May 15;899:174008
pubmed: 33705800
Lancet Neurol. 2014 Sep;13(9):924-35
pubmed: 25142459
Pain. 1988 Jan;32(1):77-88
pubmed: 3340425
J Neurochem. 2014 Nov;131(4):413-7
pubmed: 25051888
J Pain. 2010 Sep;11(9):864-75
pubmed: 20338826
Mol Neurobiol. 2020 Apr;57(4):1814-1827
pubmed: 31838720
Restor Neurol Neurosci. 2018;36(5):659-668
pubmed: 30040768
Vet Rec. 1985 Apr 20;116(16):431-6
pubmed: 3923690
J Neurotrauma. 2008 May;25(5):427-48
pubmed: 18338959
Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):679-89
pubmed: 24722818
Int J Mol Med. 2020 May;45(5):1373-1384
pubmed: 32323731
Int J Mol Sci. 2019 May 17;20(10):
pubmed: 31108947
J Rehabil Res Dev. 2009;46(1):13-29
pubmed: 19533517
J Neurotrauma. 2006 May;23(5):635-59
pubmed: 16689667
Oncol Rep. 2018 Jun;39(6):3007-3014
pubmed: 29693189
BMC Complement Med Ther. 2020 Jan 15;20(1):9
pubmed: 32020872
Pain. 2003 Jun;103(3):249-257
pubmed: 12791431
J Neurosci. 2000 Jan 1;20(1):251-8
pubmed: 10627602
Brain Res Mol Brain Res. 2005 Aug 18;138(2):244-55
pubmed: 15922485
J Neurosci. 2006 Oct 11;26(41):10488-98
pubmed: 17035533
Inflamm Res. 2014 Jan;63(1):81-90
pubmed: 24127072
Pain. 2005 Mar;114(1-2):149-59
pubmed: 15733640
J Toxicol Sci. 2020;45(9):515-537
pubmed: 32879252
Curr Drug Targets. 2017;18(2):160-173
pubmed: 27231108
Eur J Neurosci. 2005 Dec;22(11):2775-82
pubmed: 16324111
Neurochem Res. 2015 Aug;40(8):1655-60
pubmed: 26134310
Annu Rev Pharmacol Toxicol. 1980;20:441-62
pubmed: 7387124
Somatosens Mot Res. 2019 Mar;36(1):14-23
pubmed: 30870070
Int Immunopharmacol. 2019 Jan;66:19-27
pubmed: 30419450
Life Sci. 2013 Jul 10;92(24-26):1215-21
pubmed: 23688865
Int J Mol Sci. 2010 Feb 04;11(2):622-46
pubmed: 20386657
Glia. 2019 May;67(5):935-949
pubmed: 30585356
Exp Neurol. 2012 Apr;234(2):283-92
pubmed: 21946268
J Neurotrauma. 2011 Apr;28(4):619-34
pubmed: 21265596
Sci Rep. 2018 Mar 1;8(1):3873
pubmed: 29497125
Eur J Neurosci. 1995 Feb 1;7(2):305-17
pubmed: 7757265
Nat Rev Dis Primers. 2017 Feb 16;3:17002
pubmed: 28205574
Vascul Pharmacol. 2018 Sep;108:23-35
pubmed: 29678603
J Neurosci. 2009 Apr 1;29(13):4096-108
pubmed: 19339605
Mol Med Rep. 2015 Aug;12(2):3017-24
pubmed: 25955644
Mol Brain. 2020 Apr 29;13(1):64
pubmed: 32349774
J Neuroinflammation. 2020 Oct 21;17(1):311
pubmed: 33081801
Rev Neurol (Paris). 2019 Jan - Feb;175(1-2):46-50
pubmed: 30318260
Brain Res. 2010 Mar 31;1322:8-23
pubmed: 20138844